YTH结构域N6-甲基腺嘌呤RNA结合蛋白2的生物学作用及其在肿瘤中应用的研究进展  

The biological role of YTHDF2 and its application in tumors

作　　者：施邓鑫杰 施鸿金 张楠[2] 付什 王群 董昊楠 王剑松[1] 李海丹[1] 王海峰 SHI Dengxinjie;SHI Hongjin;ZHANG Nan;FU Shi;WANG Qun;DONG Haonan;WANG Jiansong;LI Haidan;WANG Haifeng(Department of Urology,the Second Affiliated Hospital of Kunming Medical University,Kunming 650000,Yunnan,China;不详)

机构地区：[1]昆明医科大学第二附属医院泌尿外科,云南昆明650000 [2]昆明市中医医院泌尿外科,云南昆明650000

出　　处：《实用医学杂志》2025年第4期615-620,共6页The Journal of Practical Medicine

基　　金：国家自然科学基金资助项目(编号:82260609);云南省科技厅基础研究项目(编号:202201AS070085,202101AY070001-137);云南省教育厅科学研究基金项目(编号:2024Y231);昆明医科大学研究生创新基金(编号:2024B025)。

摘　　要：YTH结构域N6-甲基腺嘌呤RNA结合蛋白2(YTH domain N6-methyladenine RNA binding pro⁃tein 2,YTHDF2)是一种关键的m6A RNA修饰“阅读器”,在细胞生物学过程和肿瘤发展中发挥着至关重要的作用。该综述深入探讨了YTHDF2的生物学作用及其在肿瘤中应用的研究进展。YTHDF2结构分为mRNA加工体和YTH结构域,可识别并结合m6A修饰的RNA分子。它在细胞内通过促进mRNA降解、调节细胞信号通路和代谢等发挥生物学作用,在肿瘤微环境中可调节巨噬细胞功能和维持免疫抑制状态。YTHDF2在不同肿瘤中具有作为诊断标志物、治疗靶点和预后评估生物标志物的潜力,但目前相关研究在样本规模、分子机制和临床应用等方面仍存在不足。未来可从开展全面临床研究、深入解析分子机制和研发优化治疗策略等方面进行研究。YTHDF2 is a key m6A RNA modification"reader"that plays a crucial role in cell biological processes and tumor development.This review deeply explores the biological role of YTHDF2 and the advances in its application in tumors.The YTHDF2 structures are divided into mRNA procsomes and YTH domains,which recognize and bind m6A modified RNA molecules.It plays a biological role by promoting mRNA degradation,regu⁃lating cell signaling pathways and metabolism,and can regulate macrophage function and maintain an immunosup⁃pressive state in the tumor microenvironment.YTHDF2 has the potential to serve as diagnostic markers,therapeu⁃tic targets and prognostic evaluation biomarkers in different tumors,but currently relevant studies are insufficient in sample size,molecular mechanism and clinical application.In the future,research can be conducted on compre⁃hensive clinical research,in-depth analysis of molecular mechanisms,and research and development of optimized treatment strategies.

关 键 词：YTHDF2 m6A修饰 生物学作用 肿瘤 诊断标志物 治疗靶点 预后评估 

分 类 号：R73-31[医药卫生—肿瘤]